1例支架内再狭窄患者药物治疗分析及思考  

Analysis on Drug Therapy in a Patient with In-stent Restenosis

作　　者：胡扬[1] 任文静[2] 梅丹[1] 田庄[3] 顾晴[3] 

机构地区：[1]中国医学科学院北京协和医院药剂科,北京100730 [2]解放军307医院药学部,北京100071 [3]中国医学科学院北京协和医院心内科,北京100730

出　　处：《中国药学杂志》2017年第22期2047-2050,共4页Chinese Pharmaceutical Journal

摘　　要：目的由1例支架内再狭窄患者药物治疗过程的回顾和讨论,探讨临床药师在心血管内科开展工作的模式。方法临床药师通过回顾文献、深入问诊、寻找证据,提出致支架内再狭窄的2种可能性,患者用药依从性差或药品质量问题,提出可行性建议,并协助制定药物治疗方案。结果患者住院连续服用8 d双联抗血小板药物后,症状改善,实验室指标显示血小板抑制率良好。第5个月随访,患者未出现不适症状及出血事件。结论临床药师在诊疗活动中及时甄别不良事件中的药物因素,制定个体化药物治疗方案,保障患者用药安全性、有效性和经济性。OBJECTIVE To discuss the drug therapy in a patient with in-stent restenosis, and explore the work forms of pharmacists in the department of cardiology. METHODS Two causes for in-stent restenosis were summarized by pharmacists, which the patient was noncompliance or poor quality of drugs. Then pharmacists gave feasible suggestions to improve drug therapy by searching literatures and consulting patients. RESULTS After regular administration of aspirin in our hospital, the symptoms improved and laboratory test showed poor. The outcome of follow-up in 5th month is normal. CONCLUSION Pharmacists identify adverse events and help physicians to make individual drug therapy to ensure patient safety, effectiveness and economy.

关 键 词：临床药师 支架内再狭窄 阿司匹林抵抗 血栓弹力图 血小板聚集试验 

分 类 号：R969.3[医药卫生—药理学]